CN104540514B - 治疗癌症相关性疲劳的组合物 - Google Patents

治疗癌症相关性疲劳的组合物 Download PDF

Info

Publication number
CN104540514B
CN104540514B CN201380039163.4A CN201380039163A CN104540514B CN 104540514 B CN104540514 B CN 104540514B CN 201380039163 A CN201380039163 A CN 201380039163A CN 104540514 B CN104540514 B CN 104540514B
Authority
CN
China
Prior art keywords
extract
ginger
composition
cancer
ginseng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380039163.4A
Other languages
English (en)
Other versions
CN104540514A (zh
Inventor
E·邦巴尔代利
F·科尔蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Publication of CN104540514A publication Critical patent/CN104540514A/zh
Application granted granted Critical
Publication of CN104540514B publication Critical patent/CN104540514B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9068Zingiber, e.g. garden ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明公开组合物,该组合物含有作为活性成分的(a)人参,(b)姜,(c)狭叶紫锥菊和(d)水飞蓟的提取物或水飞蓟素和磷脂的磷脂复合物以及合适的赋形剂。

Description

治疗癌症相关性疲劳的组合物
技术领域
本发明涉及含有人参(Panax ginseng C.A.Mayer)、生姜(Zingiberofficinale)、狭叶紫锥菊(Echinacea angustifolia)和水飞蓟(Silybum marianum)提取物的制剂。本发明的组合物可以用于治疗癌症患者的疲劳感。
背景技术
目前可利用的有效治疗癌症的方法使得“长期幸存者”的人数显著增加,这使得保证这些患者的日见提高的生活品质这一基本问题更加突出。癌症相关性疲劳感是难以界定的宽泛性症状,从社会心理学意义上讲其极大地损害了患者的生活品质。尽管其起源是多因素的并且以生理学为基础,但是其感知仍然是个体化的,并且与复杂的心理学概念有关。其基本特征为虚弱,也就是发挥最大肌肉力量的能力降低,且容易疲劳,换言之,是不能长时间维持一项活动。一些研究人员试图确定疲劳的原因源于肌肉无力的状态,而另一些人员则从行为学的角度认为疲劳的原因主要源于身体不适的普遍状态。癌症相关性疲劳是一种严重的症状,影响了28-90%的癌症患者以及80-90%的经过化疗和放疗的癌症患者,并且甚至在停止治疗后还会长期损害患者的生活品质[CA:Cancer J.Cli.,2012,62(1),10-29]。癌症相关性疲劳与由于工作或压力引起的患者通过休息就可以恢复的普通疲劳非常不同。据称,超过75%的癌症患者过度疲倦,伴有非常严重、需要异常休息的全身性虚弱,而且这种虚弱往往是不能恢复的。还据称,极大部分的患者还缺乏动力,伴有焦虑、呼吸问题,认知障碍和睡眠不足导致的疲惫。此种综合征常伴有弥漫性疼痛,因此导致患者在维持治疗过程中的依从性降低,更重要的是,这些恢复过程仍然处于工龄期。化疗和放疗是对抗癌症必不可少的手段,但是这些手段会诱发一系列不良反应,诸如全身性炎症、肝毒性、肾毒性和神经系统损害,这些均导致严重的身体虚弱。此外,在癌症治疗中常见的免疫系统损伤会产生免疫抑制症状,这些症状会使得患者更容易受到其它感染原的攻击。另外,放射治疗也会导致贫血、消瘦、厌食、恶心和周围神经病变。
这些复杂的临床表现严重影响了患者的生活品质。尽管人们为了改善这些症状已经作出了各种尝试,但还是收效甚微。
目前对症疗法中使用的药物包括:COX-2抑制剂,如用于提高注意力和警觉性的哌醋甲酯,类固醇激素和糖皮质激素,但是这些药物都有严重的毒副作用,并且有时风险效益严重不成比例,最重要的是,在这些对症疗法中常用药物的配伍使用难度很大。
在这样的情况下,提出了以例如药用植物提取物的天然物质作为药物的治疗方法。
一个例子是众所周知的具有抗疲劳和增加活力作用的人参提取物,该提取物具有免疫刺激和抗癌特性。一项研究[Proc.Am.Soc.Clin.Oncol.2003Abst.2947]已经得出了令人鼓舞的结果,即与安慰剂组相比,人参提取物使用组有着显著的疲劳改善作用。然而,或许是由于制剂的非标准化,在其他研究中,结果是不稳定或可疑的,有时甚至是不利的。
水飞蓟素是一种存在于水飞蓟提取物中的物质,在实验动物模型和人体临床试验得到证实,该物质可以有效保护细胞对抗细胞毒性物质并且在各种病理条件下支持肝功能发挥正常作用。即使在肠胃功能下降的状况下,水飞蓟素与磷脂的复合物仍会促进它的吸收。在癌症患者的对症疗法的特殊领域,在对年轻患者进行的一项近期研究表明,水飞蓟素在急性成淋巴细胞白血病的典型治疗中具有很高的安全水平并有利降低了肝毒性指数[Cancer,2010,116,506-13.]。
由于姜辣素及其同种物的抗炎作用,生姜可以通过减轻与促炎细胞因子释放有关的炎症状态而起作用,进而提高患者的生活品质。此外,由于众所周知的抗恶心作用,众多的研究已经证明,生姜可以有效治疗癌症患者高频早发的恶心症状,甚至是在不存在致吐物质(化疗药物)的情况下[Support Care Cancer,2012,20(7),1479-89].
具有免疫刺激特性的紫锥菊提取物,能够提高免疫抑制,可以防止感染过程的发作和可严重影响患者幸福感和生活品质的腐生菌的侵袭[Int Immunol.Pharmacol.9,850-85,2009]。此外,狭叶紫锥菊烷基酰胺具有与已知的甾体和非甾体抗炎药相比拟的抗炎和镇痛作用,但是具有下列优点:吸收更快,不影响花生四烯酸级联和随之而发生的胃损伤,并且能够以足够的量到达脑部并与大麻素受体互相作用,它们可以调节止痛和症状反应。
发明内容
申请人业已发现,人参、生姜、狭叶紫雏菊和水飞蓟提取物的组合具有协同作用,因而比任何一种植物的单一提取物都可以更加有利地从本质上影响疾病。
因此,本发明提供包括作为活性成分的人参、生姜、狭叶紫雏菊和水飞蓟提取物以及适当的赋形剂的组合物。
本发明的活性成分是已知的,可通过商业途径获得或者可以通过已知的方法进行制备。
优选人参提取物获自至少四年以上的人参根部,采用水和乙醇混合物进行提取。得到的提取液中含有8%的人参皂苷,人参皂苷Rg1/人参皂苷Rb1的比例为0.5/1。
优选生姜提取物为亲脂性提取物,在超临界条件下用二氧化碳,由植物的根和根茎提取,在230bar-260bar的压力下,于萃取器中从根中提取出粉末,优选235bar,温度范围为40-60℃,优选50℃,时间范围为1-10小时,优选7小时;在冷凝器中收集提取液,经溶于正己烷或庚烷中的惰性气体脱水,并在40℃以下、于真空中浓缩。所述提取物含有约30%的姜辣素,可以直接用于本发明的制剂中。
狭叶紫雏菊的提取物可以根据EP464298中所述在超临界二氧化碳条件下获得。亲脂性提取物中的异丁酰胺的重量比超过20%。
虽然可以使用水飞蓟的商业提取物或其主要成分西利马林(silymarin)(水飞蓟素、异水飞蓟素和次水飞蓟素的混合物),但是优选使用如EP209038所述获得的水飞蓟素和脂类的复合物,特别是大豆卵磷脂类或卵磷脂。
每个给药剂型中活性成分的剂量大约在如下指定的范围内:
-人参:提取物10-500mg,优选50-250mg;
-生姜:提取物5-100mg,优选10-50mg;
-紫锥菊提取物:提取物1-50mg,优选5-20mg;
-水飞蓟素和磷脂的复合物:10-500mg,优选50-250mg。
优选这些剂量每日口服一至四次,优选每日三次。
可以根据如《雷明顿药物手册(Remington’s Pharmaceutical Handbook)》(MackPublishing Co.,N.Y.,USA)中所描述的常规方法,将本发明的组合物配制成制剂。具体而言,可以根据常规植物成分制剂技术,将本发明的组合物配制成制剂,需要特别小心的是要避免赋形剂与胶囊基材之间的相互作用。口服制剂的示例有片剂、糖衣丸、软明胶胶囊、硬明胶胶囊以及纤维素胶囊。
根据另一个方面,本发明的组合物可以与其它有用的或具有互补效应的药物组合使用,可以使易感的患者对未来的治疗有更好的抵抗和更少的复发。
具体的实施方式
以下实施例进一步阐述了本发明。
实施例1
单位组成(薄膜包衣片)
Figure BDA0000660484160000041
Figure BDA0000660484160000051
实施例2-临床试验
为了研究联合用药的效能,选取了有癌症相关性疲劳病史的成年患者。ESAS(埃德蒙顿症状评估量表)是对症疗法中一个评定症状的得到认可的工具,被用来评价主要指标(primary endpoints)。ESAS级别可以评价9种不同的症状,分为从0-10的计分参数,其中0代表没有症状,10则代表症状中最严重的形式。还引入了十分之一这个参数(生活品质),源于九个指标的平均得分。
选择患者时,纳入的第一个标准是疲劳感存在至少一个月并且预期寿命至少8个月。
组合产品,该组合产品含有下列成分:
-100mg含有8%的人参皂苷的人参提取物,其人参皂苷Rg1和人参皂苷Rb1比例为0.5/1,该提取物由至少4年的主根茎通过水-乙醇提取制备。
-20mg生姜的亲脂提取物,其中含有25%的姜辣素和生姜酚,
-5mg狭叶紫锥菊的亲脂性提取物,其中含有25%的异丁酰胺,
-100mg比例为1:2的水飞蓟素和磷脂的复合物(卵磷脂30%),
将所述组合产品给药于因原发性肺、前列腺、胰腺和结肠肿瘤而进行过放疗和化疗的男性患者60天,每天三次,每次两片,饭前30分钟服用(早餐,午餐和晚餐)。提取物被配制成470mg的片剂。
将患者分为5组,按如下方案进行治疗:
第1组:安慰剂治疗(实施例1所述的组合物中使用的赋形剂);
第2组:用实施例1所述的组合物进行治疗;
第3组:用生姜/紫锥菊组合物(与实施例1中所述的剂量相同)进行治疗;
第4组:仅用水飞蓟素磷脂复合物(与实施例1中所述的剂量相同)进行治疗;
第5组:用人参提取物(与实施例1中所述的剂量相同)进行治疗;
临床试验的结果列于下表。
Figure BDA0000660484160000061
正如这些数据所示,实施例1所述的组合物对于生命力和外周痛有显著的效果,可以明显改善患者的情绪,提高食欲,可能是由于加速了胃排空和降低了恶心感或改善了肝功能所致。通过将实施例1所述的组合物和其他治疗的结果进行直接比较表明,表示生活品质的该组患者的平均得分恢复到正常状态(比分0-3),而安慰剂组仍处于病理状态(得分6-7),其他组则在亚临床状态(评分5-6),尽管有一些参数发生了预期的改善。生活品质的重大出人意料的改善激活了一个对机体有利的过程,增加了对于蛋白类食物的欲望,这或许是因为肝的再激活和肠道运输功能的改善,或许是由于水飞蓟素和磷脂复合物的利胆作用。蛋白类食物的摄取,伴随着肌肉群的恢复和体育运动,可以逆转异化趋势,减轻疲劳感,正如一些研究所表明的那样,这明显有助于患者的社会心理方面的康复。

Claims (4)

1.组合物用于制备治疗选自疼痛、虚弱、沮丧、焦虑、食欲不振、生活品质的癌症相关性疲劳的药物的用途,该组合物含有作为活性成分的下列组分以及合适的赋形剂:
(a)人参提取物,
(b)生姜提取物,
(c)狭叶紫锥菊提取物,和
(d)水飞蓟素与磷脂的磷脂复合物。
2.根据权利要求1的用途,其中所述生姜和狭叶紫锥菊提取物为亲脂性提取物。
3.根据权利要求1的用途,其中所述人参提取物中含有8%的人参皂苷,人参皂苷Rg1和Rb1的比例为0.5/1,生姜提取物含有30%的姜辣素,且狭叶紫锥菊提取物中异丁酰胺的重量比高于20%。
4.根据权利要求1-3中任一项的用途,其中该药物为片剂、糖衣丸、软明胶胶囊、硬明胶胶囊或纤维素胶囊的形式。
CN201380039163.4A 2012-07-27 2013-07-11 治疗癌症相关性疲劳的组合物 Expired - Fee Related CN104540514B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001317A ITMI20121317A1 (it) 2012-07-27 2012-07-27 Composizioni per il trattamento della fatica oncologica
ITMI2012A001317 2012-07-27
PCT/EP2013/064711 WO2014016137A1 (en) 2012-07-27 2013-07-11 Compositions for treatment of cancer-related fatigue

Publications (2)

Publication Number Publication Date
CN104540514A CN104540514A (zh) 2015-04-22
CN104540514B true CN104540514B (zh) 2020-03-27

Family

ID=46939795

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380039163.4A Expired - Fee Related CN104540514B (zh) 2012-07-27 2013-07-11 治疗癌症相关性疲劳的组合物

Country Status (22)

Country Link
US (1) US9566309B2 (zh)
EP (1) EP2877192B1 (zh)
JP (1) JP6129314B2 (zh)
KR (1) KR102091128B1 (zh)
CN (1) CN104540514B (zh)
AU (1) AU2013295227B2 (zh)
BR (1) BR112015001174B1 (zh)
CA (1) CA2879906A1 (zh)
DK (1) DK2877192T3 (zh)
ES (1) ES2590209T3 (zh)
HK (1) HK1209375A1 (zh)
HR (1) HRP20160774T1 (zh)
HU (1) HUE030002T2 (zh)
IL (1) IL236871B (zh)
IN (1) IN2015KN00222A (zh)
IT (1) ITMI20121317A1 (zh)
PL (1) PL2877192T3 (zh)
PT (1) PT2877192T (zh)
RU (1) RU2631612C2 (zh)
SG (1) SG11201500521XA (zh)
SI (1) SI2877192T1 (zh)
WO (1) WO2014016137A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658227B (zh) * 2013-08-30 2020-04-03 绿十字生命健康有限公司 含有人参皂苷成分得到增加的加工人参粉末或加工人参提取物的用于预防及治疗癌因性疲乏的组合物
EP3389644B1 (en) * 2015-12-16 2022-01-26 Parachur, Vivek Anand Tri-molecular complex of natural compounds
EP3335716A1 (en) * 2016-12-15 2018-06-20 Indena S.p.A. Process for the preparation of powder compositions
AU2022277553A1 (en) 2021-05-18 2023-11-09 Prostasis, Llc Compositions comprising mixtures of compounds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101502320A (zh) * 2009-03-11 2009-08-12 王越 一种参姜红枣饮料冲剂的生产方法
CN102281889A (zh) * 2009-01-20 2011-12-14 因德纳有限公司 用于预防和治疗胃-食道返流和化学治疗诱导的呕吐的包含姜和狭叶紫锥菊的亲脂提取物的组合物
WO2012013551A1 (en) * 2010-07-26 2012-02-02 Indena S.P.A. Formulations containing extracts of echinacea angustifolia and zingiber officinale which are useful in reducing inflammation and peripheral pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1215291B (it) * 1985-07-17 1990-01-31 Inverni Della Beffa Spa Complessi di flavanolignani con fosfolipidi, loro preparazione e relative composizioni farmaceutiche.
ATE123947T1 (de) 1990-07-05 1995-07-15 Indena Spa Echinacea-extrakte, verfahren zur herstellung und zubereitungen, die sie enthalten.
CZ292832B6 (cs) * 2001-08-30 2003-12-17 Ivax Pharmaceuticals S.R.O. Způsob přípravy silymarinu se zvýšenou rozpustností
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20050002962A1 (en) * 2003-04-16 2005-01-06 David Pasco Immunostimulatory agents in botanicals
US20050031710A1 (en) * 2003-08-08 2005-02-10 D'adamo Peter James Method of personal care and cosmetic product preparation and composition using human blood type
RU2277927C2 (ru) * 2004-09-15 2006-06-20 Наталья Ивановна Весельева Лечебно-профилактический комплекс "бальзам долголетие" общеукрепляющего и тонизирующего действия (варианты)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102281889A (zh) * 2009-01-20 2011-12-14 因德纳有限公司 用于预防和治疗胃-食道返流和化学治疗诱导的呕吐的包含姜和狭叶紫锥菊的亲脂提取物的组合物
CN101502320A (zh) * 2009-03-11 2009-08-12 王越 一种参姜红枣饮料冲剂的生产方法
WO2012013551A1 (en) * 2010-07-26 2012-02-02 Indena S.P.A. Formulations containing extracts of echinacea angustifolia and zingiber officinale which are useful in reducing inflammation and peripheral pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
中药有效成分抗氧化作用的实验研究;孟申等;《中国药理学通报》;19921025;第8卷(第05期);326-330 *

Also Published As

Publication number Publication date
JP6129314B2 (ja) 2017-05-17
ITMI20121317A1 (it) 2014-01-28
AU2013295227A1 (en) 2015-02-19
IN2015KN00222A (zh) 2015-06-12
KR20150037890A (ko) 2015-04-08
CA2879906A1 (en) 2014-01-30
BR112015001174B1 (pt) 2021-02-02
CN104540514A (zh) 2015-04-22
SI2877192T1 (sl) 2016-09-30
ES2590209T3 (es) 2016-11-18
DK2877192T3 (en) 2016-09-05
PL2877192T3 (pl) 2016-12-30
AU2013295227B2 (en) 2017-04-27
WO2014016137A1 (en) 2014-01-30
KR102091128B1 (ko) 2020-03-20
SG11201500521XA (en) 2015-02-27
US20150202246A1 (en) 2015-07-23
EP2877192A1 (en) 2015-06-03
PT2877192T (pt) 2016-09-13
RU2015102002A (ru) 2016-09-20
HUE030002T2 (en) 2017-04-28
IL236871B (en) 2018-01-31
EP2877192B1 (en) 2016-06-08
US9566309B2 (en) 2017-02-14
HRP20160774T1 (hr) 2016-08-12
JP2015522631A (ja) 2015-08-06
HK1209375A1 (zh) 2016-04-01
BR112015001174A2 (pt) 2017-06-27
RU2631612C2 (ru) 2017-09-25

Similar Documents

Publication Publication Date Title
US7976880B2 (en) Pregnane glycoside compositions and Caralluma extract products and uses thereof
US20160166631A1 (en) Nutraceutical combination for prevention and treatment of type 2 diabetes
US8859019B2 (en) Compositions comprising lipophilic extracts of Zingiber officinale and Echinacea angustifolia for the prevention and treatment of gastro-oesophageal reflux and chemotherapy-induced emesis
CN104540514B (zh) 治疗癌症相关性疲劳的组合物
AU2010206327B2 (en) Compositions comprising a lipophilic extract of Zingiber officinale and an extract of Cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome
CN110996987A (zh) 用于调控应激障碍中激素级联的组合物和方法
US9901610B2 (en) Formulations for the treatment and prevention of obesity
EP2586452A1 (en) Use of a chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction
US6649185B2 (en) Herbal formulation
JP5950493B2 (ja) 疲労回復剤
US20170095522A1 (en) Compositions Containing Extracts of Curcuma SPP and Zingiber officinale Which Are Useful to Reduce Peripheral Inflammation and Pain
EP3914237A1 (en) Olive fruit extract suitable for reducing body-mass index and visceral fat in overweight subjects
JP2023536053A (ja) イトヒメハギの乾燥根の抽出物を含有する組成物
CN104473957B (zh) 一种用于降脂的中药单体组合物及其制剂
CN116211907A (zh) 挥发油及其用于治疗或改善男性性功能障碍的用途
TW201733572A (zh) 用於預防及治療第2型糖尿病之營養品組合

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1209375

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200327

Termination date: 20210711

CF01 Termination of patent right due to non-payment of annual fee